Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Average Price Target from Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $10.00.

PYXS has been the subject of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, November 21st. Royal Bank of Canada boosted their price target on Pyxis Oncology from $7.00 to $10.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Stephens began coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They issued an "overweight" rating and a $13.00 target price on the stock. Finally, William Blair lowered Pyxis Oncology from an "outperform" rating to a "market perform" rating in a research note on Thursday, November 21st.

Insider Activity

In other news, CFO Pamela Ann Connealy purchased 88,850 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The shares were acquired at an average cost of $1.96 per share, with a total value of $174,146.00. Following the transaction, the chief financial officer now owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. The trade was a 8.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.80% of the company's stock.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its position in shares of Pyxis Oncology by 275.0% during the third quarter. Barclays PLC now owns 64,089 shares of the company's stock worth $235,000 after acquiring an additional 46,997 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Pyxis Oncology by 5.5% during the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company's stock valued at $3,982,000 after buying an additional 57,016 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Pyxis Oncology during the third quarter valued at approximately $107,000. XTX Topco Ltd boosted its position in shares of Pyxis Oncology by 133.6% during the third quarter. XTX Topco Ltd now owns 84,771 shares of the company's stock worth $311,000 after buying an additional 48,481 shares during the period. Finally, Jane Street Group LLC grew its holdings in Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company's stock worth $182,000 after buying an additional 14,349 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Stock Up 6.6 %

Shares of NASDAQ PYXS traded up $0.10 on Friday, hitting $1.62. The company's stock had a trading volume of 906,487 shares, compared to its average volume of 789,662. The stock has a 50 day moving average of $3.13 and a 200-day moving average of $3.39. Pyxis Oncology has a 12-month low of $1.51 and a 12-month high of $6.85.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.